Hereditary Angioedema
10 competing products in clinical development for Hereditary Angioedema.
Pipeline by Phase
Pre-clinical2
Phase 13
Phase 21
Phase 34
All Products (10)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | Active | 72 |
| Placebo + KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | Completed | 72 |
| KVD900 150 mg + KVD900 300 mg + KVD900 600 mg | KalVista Pharmaceuticals | Phase 3 | Completed | 72 |
| KVD900 600 mg + Drug: KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | Active | 72 |
| KVD900 | KalVista Pharmaceuticals | Phase 2 | Completed | 47 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 1 | Completed | 28 |
| KVD900 + Placebo to KVD900 | KalVista Pharmaceuticals | Phase 1 | Completed | 28 |
| KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tablet | KalVista Pharmaceuticals | Phase 1 | Completed | 28 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | Completed | 18 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | Active | 18 |